Continuous glucose monitoring-enabled insulin-pump therapy in diabetic pregnancy.
Summary of "Continuous glucose monitoring-enabled insulin-pump therapy in diabetic pregnancy."
Abstract We describe the feasibility of continuous glucose monitoring (CGM)-enabled insulin-pump therapy during pregnancy in a woman with type 1 diabetes, who was treated with CGM-enabled insulin-pump therapy in her third pregnancy. During her first pregnancy, the woman was treated with multiple daily injections and baseline HbA1c was 8.9%. Due to pre-eclampsia, the child was born preterm, and had neonatal hypoglycemia. In the planning of the second pregnancy, insulin-pump therapy was initiated, resulting in an HbA1c of 6.8% in early pregnancy. Due to pre-eclampsia, the second child was born preterm, but without neonatal morbidity. Before her third pregnancy, CGM-enabled insulin-pump therapy was introduced, and HbA1c was 6.4% in early pregnancy. The patient was satisfied with this therapy, pre-eclampsia did not occur, and the child was born at term without neonatal morbidity. CGM-enabled insulin-pump therapy appears feasible in diabetic pregnancies.
Affiliation
Center for Pregnant Women with Diabetes, Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark.
Journal Details
This article was published in the following journal.
Name: Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Pages: 1233-7
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20804351
- DOI: http://dx.doi.org/10.3109/00016349.2010.498499
Medical and Biotech [MESH] Definitions
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. It can be caused by the presence of INSULIN ANTIBODIES or the abnormalities in insulin receptors (RECEPTOR, INSULIN) on target cell surfaces. It is often associated with OBESITY; DIABETIC KETOACIDOSIS; INFECTION; and certain rare conditions. (from Stedman, 25th ed)
Blood Glucose Self-monitoring
Self evaluation of whole blood glucose levels outside the clinical laboratory. A digital or battery-operated reflectance meter may be used. It has wide application in controlling unstable insulin-dependent diabetes.
Insulin
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
Glucose Clamp Technique
Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.
Glucose Transporter Type 2
A glucose transport facilitator that is expressed primarily in PANCREATIC BETA CELLS; LIVER; and KIDNEYS. It may function as a GLUCOSE sensor to regulate INSULIN release and glucose HOMEOSTASIS.
PubMed Articles
AIM: This study aimed to assess the effectiveness of continuous glucose monitoring (CGM) for glucose control in type 1 diabetic patients treated by continuous subcutaneous insulin infusion (CSII) and...
Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes.
To the Editor: In their report on the Sensor-Augmented Pump Therapy for A1C Reduction (STAR) 3 study, Bergenstal et al. (July 22 issue) report that sensor-augmented insulin-pump therapy was more effec...
Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes.
To the Editor: In their report on the Sensor-Augmented Pump Therapy for A1C Reduction (STAR) 3 study, Bergenstal et al. (July 22 issue) report that sensor-augmented insulin-pump therapy was more effec...
Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes.
To the Editor: In their report on the Sensor-Augmented Pump Therapy for A1C Reduction (STAR) 3 study, Bergenstal et al. (July 22 issue) report that sensor-augmented insulin-pump therapy was more effec...
Abstract Background: It is generally held that basal insulin substitution with continuous subcutaneous insulin infusion (CSII) provides less variable glucose levels than with long-acting insulin analo...
Clinical Trials
Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis
A pilot study to assess the safety, feasibility, and potential (uncontrolled) efficacy of continuous glucose monitoring (CGMS) in conjunction with an insulin pump to improve glycemic contr...
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c
The primary objective of this study is to evaluate whether the patients with Type 1 diabetes mellitus in sub-optimal glycemic control can achieve better glycemic control by using the Medtr...
We wish to find out if in non-diabetic pregnancies, as well as diabetic pregnancies, additional data obtained by Continuous Glucose Monitoring improves perinatal risk prediction.
Effect of CSII and CGM on Progression of Late Diabetic Complications
The purpose of the study is to investigate whether the combination of insulin pump therapy and continued glucose monitoring (CGM) is superior to multiple daily insulin injections to preven...
Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes
This study plans to link two existing technologies, the insulin pump and the continuous glucose monitor (CGM), to essentially develop an artificial pancreas, i.e., closed-loop. This will b...
